Angiotensin II (AngII) initiates cellular effects via its G protein-coupled AT1 receptor (AT1R).
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INTRODUCTION
Angiotensin II (AngII), the vasoactive hormone of the renin-angiotensin system, initiates its cellular effects through activation of its cognate seven transmembrane-spanning G proteincoupled receptor, angiotensin AT 1A receptor (AT 1A R). Interaction of AngII with the AT 1A R initiates conformational changes in the receptor, producing activation of its targeted G protein, G q/11 . Subsequent to receptor-mediated activation of G q/11 , a cascade of intracellular signaling events occurs, including acute activation of phospholipase C, release of intracellular stores of calcium and subsequent activation of numerous kinases including p42/44 ERK (Millan et al., 1991; de Gasparo et al., 2000) and chronic cellular effects including induced protein synthesis of renin, angiotensinogen and cyclooxygenase 2 (COX-2) (Eggena et al., 1993; Ohnaka et al., 2000; Morinelli et al., 2008) .
Subsequent to G protein activation, GPCRs undergo β-arrestin-mediated internalization. In addition to serving as a means to interrupt cell signaling from the cell surface, receptor internalization also serves to continue the signaling cascade within the cell. This process, in which internalized endosomes containing de-sensitized receptors along with attached β-arrestins act as a scaffold, interacting with specific signaling proteins such as p42/44 ERK, has been described as a signalsome (Luttrell et al., 2001) . These "signalsomes' are responsible for the prolonged activation of p42/44 ERK by GPCR agonists such as AngII.
In addition to the above-mentioned role of receptor trafficking in desensitization/recycling and cytoplasmic signaling, an additional pathway for GPCR trafficking has been proposed, namely localization of the activated receptor to the nuclear area. (Re et al., 1983; Eggena et al., 1993) . Lu et al demonstrated nuclear translocation of the AT 1A R in response to cellular activation by AngII (Lu et al., 1998) . We have previously shown that nuclear localization of the receptor This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on April 7, 2009 as DOI: 10.1124 at ASPET Journals on November 5, 2017 jpet.aspetjournals.org Downloaded from JPET #151829 6 may be dependent upon a putative nuclear localization sequence within the carboxy tail and that localization to the nuclear area from the plasma membrane involves clathrin-coated pits and is associated with the ability of AngII to induce COX-2 protein expression (Morinelli et al., 2007; Morinelli et al., 2008) .
The generation of prostanoids, via the activation of cyclooxygenase (COX-1 and/or COX-2), is responsible for a plethora of physiological and pathological responses. The activity of constitutive COX-1 results in the generation of prostanoids utilized to maintain physiologic homeostasis. In rat aorta vascular smooth muscle cells (RASMC), AngII induces the transcription for COX-2 via involvement of nuclear factor-κB (NF-κB) and mediation of several cytoplasmic kinases including Pyk2, MEKK4 and p38 (Ohnaka et al., 2000; Hu et al., 2002; Derbyshire et al., 2005) . Thus, AngII has been implicated in the regulation of COX-2 and the activation of several chronic disease processes mediated by COX-2.
The present study was designed to elucidate further the pathway for nuclear localization of the AT 1A R by testing the hypothesis that AngII-induced COX-2 expression in RASMC is not dependent upon the mediation of G proteins, in particular G q . To test this hypothesis, we utilized mastoparan (an activator of G proteins), suramin (an inhibitor of G protein activation), U73122 (a specific inhibitor of phospholipase C [PLC] activation) and Sarcosine 1 , Ile 4 , Ile 8 -AngII (SII-AngII) an AT 1 R agonist whose activation of cellular responses has been shown to be independent of G proteins (Wei et al., 2003) .
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METHODS
Cell culture: Primary culture of rat aorta vascular smooth muscle cells (RASMC) was performed as previously described (Morinelli et al., 2008) . Cells were maintained in Dulbecco's modified Eagle's Medium (DMEM) high glucose supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic/antimycotic/ fungizone and used between passages 3 through 8. HEK-293 cells (American Type Culture Collection) stably expressing a wild-type AT 1A R/Green Fluorescent Protein (AT 1A R/GFP) construct were maintained using Ham's F12 media supplemented with 10% FBS, 1% antibiotic/antimycotic/fungizone and G418 (400 µg/ml) (Morinelli et al., 2007) .
Cell culture media and supplements were obtained from GIBCO-BRL (Grand Island, NY).
Radioligand binding assays: Binding studies employing [
125 I]-AngII were performed as previously described (Morinelli et al., 2008) . Confluent monolayers of RASMC in 6 well plates were exposed to the various compounds for 30 min. at 37 o C. Subsequently, the growth medium containing the compounds was removed and binding buffer containing [ 125 I]-AngII (~200,000 cpm, ~100 fmoles) ± the AT1R antagonist losartan (10 µM) was added to the cells and incubation was carried out at 4°C for 90 min. Subsequently, cells were washed with cold saline buffer to remove unbound radioligand and then solubilized in 0.1% sodium dodecyl sulfate (SDS)/0.1 M NaOH and associated radioactivity counted. Specific binding was determined, i.e.
the difference between radioactivity associated with the cell lysates in the absence and presence of losartan, and corrected for total cell protein per well.
Laser scanning confocal imaging: HEK-293 cells stably expressing the wild-type AT 1A R/GFP construct were plated onto collagen-coated 25-mm glass cover slips in 6-well plates and maintained in selection medium. Prior to study, cells were deprived of serum (0.1% FBS) for 24 -48 hours. On the day of study, compounds were added directly to the media and incubated for 11 a useful cell model to visualize AT 1a R trafficking (Morinelli et al., 2007) . Addition of AngII to untreated cells produced characteristic localization of the receptor to the nuclear membrane area which has been observed previously (Morinelli et al., 2007) . G protein-mediated activation of the mitogen-activated kinase (MAPK) pathway is a central element to the hypertrophy/hyperplasia response of many GPCRs. One of the key intermediary kinases in this pathway is the serine/threonine kinase p42/44 ERK. RASMC, when exposed to AngII, produce a rapid and reversible phosphorylation of p42/44 ERK. We examined the ability of mastoparan, suramin and U73122 to influence the ability of AngII to activate this kinase.
Mastoparan, an activator of heterotrimeric G proteins, activated p42/44 ERK (Figure 4 ). This
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Having seen the varied effects of G protein interacting compounds on AngII-activated intracellular signaling, we next examined their effects on AngII-induced COX-2 expression.
RASMC were pre-treated with vehicle, mastoparan, suramin or U73122 for 30 minutes, followed by addition of buffer or AngII for an additional 3 hours, and expression of COX-2 was determined ( Figure 5 ). As seen previously, AngII increased COX-2 protein expression in a concentration-dependent manner reaching approximately a 3-fold increase at 100 nM.
Mastoparan, an activator of G proteins, which produces elevations of Ca i and activation of p42/44 ERK, also produced significant increases in the expression of COX-2. When AngII was added to mastoparan pre-treated RASMC, COX-2 expression was further increased. The G protein inhibitor suramin, which does not alter AT 1A R trafficking or p42/44 ERK activation but inhibits AngII-induced Ca i , had no effect on COX-2 expression on its own and suppressed slightly but not significantly the ability of AngII to increase COX-2 expression. U73122, an inhibitor of PLC, which does not alter AT 1A R trafficking but inhibits elevations in AngII-induced Ca i , did not inhibit AngII-induced COX-2 protein expression.
The effects seen with mastoparan, suramin and U73122 suggest that AngII-induced COX-2 expression depends partially on G protein activation and partially on AT 1A R intracellular 
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Since these data suggest that AngII activation of AT 1A Rs and subsequent COX-2 protein expression may not require the mediation of G proteins, we examined the ability of the G protein-independent AT 1A R agonist SII-AngII to activate the receptor and induce expression of COX-2. SII-AngII is a ligand of the AT 1A R that can induce receptor internalization and p42/44 ERK activation independent of G protein activation (Wei et al., 2003) . Cells exposed to SIIAngII produced endocytosis of the AT 1A R/GFP construct, which was inhibited by the AT1R antagonist losartan, and increased expression of the COX-2 protein without eliciting elevations in intracellular free calcium ( Figure 6 ).
This article has not been copyedited and formatted. The final version may differ from this version. More recent evidence points to an additional pathway for cellular responses to AngII involving the epidermal growth factor receptor (EGFR) (Shah and Catt, 2006) . In this paradigm, activation of AT1R results in metalloproteinase-dependent release of surface bound epidermal growth factor and subsequent activation of the EGFR followed by activation of its signaling pathway. Alternatively, non-G protein-dependent signaling pathways for AngII have been recently described in which the internalization of the receptor initiated by β-arrestin interaction permits subsequent prolonged activation of the MAP kinase pathway as a result of interaction of the kinases with the receptor/ β-arrestin scaffold (Pierce et al., 2000) .
In order to examine the involvement of heterotrimeric G protein activation in AngII stimulated COX-2 protein expression, we used small, cell-permeable compounds that either stimulate or inhibit G proteins. Mastoparan, a peptide derived from wasp venom, activates G proteins by promoting the exchange of GTP for GDP, thus mimicking activation of G proteins by GPCR agonists (Higashijima et al., 1988) . This tetradecapeptide has been shown to regulate of the AngII response was comparable to that seen for pre-treatment with AngII itself, ie homologous desensitization (Tang et al., 1998) . In our present studies, mastoparan also produced a densitization of the AngII-induced calcium response (a G q -PLC dependent signal) but did not inhibit AngII-induced AT 1A R trafficking and COX-2 protein expression. Mastoparan, on its own, did produce an increase in intracellular free calcium, activate p42/44 ERK and also increased COX-2 protein expression. This supports published data showing G protein activation of PLC and the p42/44 ERK pathway and also implicates this pathway in COX-2 protein expression.
Another technique for exploring the role of G proteins in the AngII-induced expression of COX-2 protein is to utilize compounds that have been shown to inhibit the activity of G proteins.
A family of small compounds that inhibit G proteins and thus inhibit the effects of GPCRs has been developed from the original suramin. Suramin inhibits G protein activity by interfering with the association of the G α and G βγ subunits, thus blocking the G protein-signaling pathway Freissmuth et al., 1996) . The ability of suramin to block G proteindependent signaling pathways has led to many studies documenting its anti-cancer effects.
However, recent evidence suggests that suramin, in certain cell types such as CHO cells and renal epithelial cells, may actually activate signaling pathways related to cell proliferation (Nakata, 2004; Zhuang and Schnellmann, 2005) . In the present study, treatment of cells with SII-AngII is a selective agonist for the AT 1A R, in that this ligand can activate β-arrestinmediated AT 1A R internalization and p42/44 ERK activation without G protein activation. In our studies, use of SII-AngII promoted internalization and nuclear membrane localization of the AT 1A R and also increased COX-2 protein expression in the absence of increases in intracellular free calcium, thus confirming lack of G protein activation in its signaling.
In summary, the present study examined the role of G protein activation in AngII-induced expression of the enzyme COX-2. Through the use of compounds that stimulate G proteins, inhibit G proteins or inhibit an enzyme activated by a G protein, we conclude that the ability of AngII to increase COX-2 expression was dependent upon normal internalization and nuclear membrane trafficking of the AT 1A R. G protein-dependent activation of PLC and subsequent elevations in intracellular free calcium is not required for this effect, since suramin or U73122
did not alter AT 1A R trafficking and did not inhibit AngII-induced COX-2 expression. Previous studies implicated activation of the MAP kinase pathway in AngII-induced COX-2 expression (Ohnaka et al., 2000) . The MAP kinase pathway may be a parallel pathway for activation of 
